PTGS2 and preeclampsia: Given (1) the widespread tissue and cellular expression of COX-2 and PAR-1 in preeclamptic pregnancy; (2) that COX-2 mediates the inflammatory effects of PAR-1; and (3) that activation of PAR-1 can explain clinical and pathologic manifestations of preeclampsia, consideration should be given to conducting a clinical trial to treat women with preeclampsia using a dose of aspirin that inhibits COX-2.